Introduction
The renin-angiotensin system (RAS) is a critical hormonal pathway regulating blood pressure and fluid balance. A key enzyme in this system, Angiotensin-Converting Enzyme (ACE), is encoded by a gene featuring a common insertion/deletion (I/D) polymorphism. While the deletion (D) allele is linked to higher circulating ACE levels and increased arterial stiffness, its association with systolic blood pressure (SBP) has been inconsistent in previous literature.
This study, published in Hypertension Research, addresses these inconsistencies by examining a genetically homogeneous population. By focusing on a rural Australian cohort, researchers aimed to determine if the ACE DD genotype serves as a specific risk factor for hypertension when compounded by Type 2 Diabetes Mellitus (T2DM).
Methods
The researchers conducted a cross-sectional analysis of 136 participants (43 with T2DM and 93 age-matched healthy controls) from the Charles Sturt University Diabetes Screening Research Initiative in rural New South Wales. The cohort was primarily of European/Caucasian ancestry, minimizing genetic "noise" often found in urban studies.
Clinical protocols involved supine blood pressure measurements taken after a 30-minute rest period. Genotyping was performed using a triple primer method followed by polyacrylamide gel electrophoresis to distinguish between DD, ID, and II genotypes. Statistical analysis utilized ANOVA and Tukey post-hoc tests to compare blood pressure across groups.
Results
The primary finding was a significant association between the ACE DD genotype and elevated SBP specifically within the T2DM group. Patients with T2DM and the DD genotype had a mean SBP of 146.8 ± 32.8 mmHg, significantly higher than T2DM patients with the ID (124.7 ± 14.2 mmHg) or II (125.6 ± 7.5 mmHg) genotypes ($P < 0.03$).
In the healthy control group, no significant differences in blood pressure were observed across genotypes. Furthermore, T2DM patients with the DD genotype had significantly higher SBP compared to healthy controls with the same genotype (146.8 vs. 121.9 mmHg, $P < 0.05$). These results suggest a recessive genetic model where the DD genotype, in the presence of diabetes, acts as a physiological trigger for hypertension.
Discussion
Despite the significantly higher SBP observed in the T2DM DD subgroup, there were no significant differences in the classes of antihypertensive medications prescribed across the T2DM genotypes.
This parity in treatment suggests that the DD subgroup may be undertreated relative to their biological risk. The authors highlight that the genetic homogeneity of rural populations allows for the detection of such significant associations even in smaller cohorts.
Limitations and Future Directions
The study's main limitation is the small sample size of the T2DM DD group ($n=9$). While the findings are statistically significant, they are considered preliminary. As a cross-sectional study, it provides a snapshot of the cohort; future longitudinal research is necessary to determine if this genetic profile leads to more rapid progression of cardiovascular complications. Clinically, these findings suggest that T2DM patients with the DD genotype may benefit from more aggressive blood pressure management, potentially prioritizing ACE inhibitors or angiotensin receptor blockers to mitigate their genetic predisposition.
Summary updated